Journal of Cardiovascular Pharmacology

Top Research Topics at Journal of Cardiovascular Pharmacology?

The journal is mainly concerned with subjects like Internal medicine, Endocrinology, Cardiology, Blood pressure and Pharmacology. Research in Anesthesia and the interrelating topic of Ischemia were among the subjects of interest in the Internal medicine studies discussed in the journal. Topics in Endocrinology were tackled in line with various other fields like Receptor, Endothelin receptor and Endothelin 1.

Cardiology research presented is mostly focused on the subject of Myocardial infarction. The Blood pressure study tackled is a key component of adjacent topics in the area of Placebo. While the journal focused on Pharmacology, it was also able to explore topics like Antagonist, Calcium and In vivo.

It focuses on Vasodilation as well as the interrelated topic of Vasoconstriction. The journal focuses on Angiotensin II research which is adjacent to topics in Renin–angiotensin system. The work tackled in the journal goes beyond the discipline of Endothelium as it also encompasses Nitric oxide.

• Internal medicine (67.28%)
• Endocrinology (47.52%)
• Cardiology (21.41%)

What are the most cited papers published in the journal?

• Nitric oxide as a signaling molecule in the vascular system: an overview. (678 citations)
• The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. (589 citations)
• The role of endothelium in cardiovascular homeostasis and diseases. (491 citations)

Research areas of the most cited articles at Journal of Cardiovascular Pharmacology:

The most cited articles focus largely on the fields of Internal medicine, Endocrinology, Pharmacology, Cardiology and Blood pressure. The works on Endocrinology tackled in the journal papers bring together disciplines like Endothelin receptor and Endothelin 1. The featured Cardiology studies in the journal articles mainly concentrate on Anesthesia but also cover areas of interest in Ischemia.

What topics the last edition of the journal is best known for?

• Internal medicine
• Enzyme
• Gene

The previous edition focused in particular on these issues:

The journal aims to foster the development of research in Internal medicine, Pharmacology, Apoptosis, Cardiology and Cell biology. Journal of Cardiovascular Pharmacology explores research in Internal medicine alongside concepts in Endocrinology and other areas of study in Receptor. While the primary focus in the journal is Pharmacology, it also dissects topics surrounding Fibrosis and Angiotensin II as a whole.

The studies on Apoptosis discussed can also contribute to research in the domains of Inflammation, Molecular biology, Flow cytometry and Downregulation and upregulation. In addition to Cell biology research, Journal of Cardiovascular Pharmacology aims to explore topics under Cell, Vascular smooth muscle, Gene knockdown and Cell growth. Some problems in Randomized controlled trial that were presented in it overlapped with concepts under Meta-analysis, Relative risk, Confidence interval and Clinical trial.

The most cited articles from the last journal are:

• Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. (8 citations)
• Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? (7 citations)
• Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. (4 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Journal of Cardiovascular Pharmacology (based on the number of publications) are:

• Paul M. Vanhoutte (81 papers) absent at the last edition,
• Fritz R. Bühler (70 papers) absent at the last edition,
• Benedict R. Lucchesi (67 papers) absent at the last edition,
• John L. Reid (55 papers) absent at the last edition,
• Alberto Zanchetti (55 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Journal of Cardiovascular Pharmacology (based on the number of publications) are:

• French Institute of Health and Medical Research (106 papers) absent at the last edition,
• University of Milan (103 papers) absent at the last edition,
• University of Michigan (98 papers) published 3 papers at the last edition,
• University of Melbourne (74 papers) absent at the last edition,
• Tohoku University (70 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 16.44% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 2.19% were posted by at least one author from the top 10 institutions publishing in the journal. Another 2.19% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 10.38% of all publications and 85.25% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities and Outlook in Cardiovascular Pharmacology

The career path in cardiovascular pharmacology offers numerous opportunities with potential for growth and development. Cardiovascular pharmacologists can work in various settings including hospitals, research institutions, universities, pharmaceutical companies and private practices. This role primarily encompasses studying the effects of drugs on heart and circulatory system function, developing new medicines, and improving existing drug treatments. Job prospects in the field of cardiovascular pharmacology are promising. The Bureau of Labor and Statistics predicts a growth in pharmacological roles, noting that employment in the sector is expected to rise faster than the average for all other occupations in the coming years. This growth can be attributed to the increasing need for innovative research and cost-effective treatment options for cardiovascular diseases. For individuals looking to pursue a career in this field, obtaining an advanced degree can greatly enhance career prospects. Those interested in cardiovascular research may wish to explore some of the best np programs in Wyoming, particularly those offering specialized courses in cardiovascular pharmacology. This could provide a strong academic and practical foundation for a successful career in this domain. As career paths and job titles can vary widely in this field, it is crucial to explore different avenues and remain open to diverse opportunities. With the right education and experience, a career in cardiovascular pharmacology can be a rewarding and impactful choice.